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Evidence is accumulating that low levels of IGF-I play a
role in the pathogenesis of type 2 diabetes and cardio-
vascular diseases. We examined the role of a genetic
polymorphism in the promoter region of the IGF-I gene
in relation to circulating IGF-I levels and growth mea-
sured as body height, and we studied the relationship of
this polymorphism with type 2 diabetes and myocardial
infarction. The relation between the IGF-I polymor-
phism and body height was assessed in a population-
based sample of 900 subjects from the Rotterdam Study.
Within each genotype stratum, 50 subjects were ran-
domly selected for a study of the relation of this poly-
morphism with serum IGF-I levels. To assess the risk for
type 2 diabetes, we studied 220 patients and 596 nor-
moglycemic control subjects. For myocardial infarction,
477 patients with evidence of myocardial infarction on
electrocardiogram and 808 control subjects were stud-
ied. A 192-bp allele was present in 88% of the popula-
tion, suggesting that this is the wild-type allele from
which all other alleles originated. Body height was, on
average, 2.7 cm lower (95% CI for difference –4.6 to
–0.8 cm, P 5 0.004), and serum IGF-I concentrations
were 18% lower (95% CI for difference –6.0 to –1.3
mmol/l, P 5 0.003) in subjects who did not carry the
192-bp allele. In noncarriers of the 192-bp allele, an
increased relative risk for type 2 diabetes (1.7 [95% CI
1.1–2.7]) and for myocardial infarction (1.7 [95% CI
1.1–2.5]) was found. In patients with type 2 diabetes,
the relative risk for myocardial infarction in subjects
without the 192-bp allele was 3.4 (95% CI 1.1–11.3). Our
study suggests that a genetically determined exposure
to relatively low IGF-I levels is associated with an
increased risk for type 2 diabetes and myocardial infarc-
tion. Diabetes 50:637–642, 2001
Insulin-like growth factor I (IGF-I) is a peptide thatstimulates bone growth, cell differentiation, andmetabolism. The structural and functional homolo-gies with insulin (1), as well as the hypoglycemic
insulin-like effects observed after the administration of
recombinant IGF-I, suggest that this peptide is involved in
the regulation of glucose homeostasis (2). In patients with
type 2 diabetes, low serum IGF-I levels are common (3,4).
Evidence is accumulating that these low IGF-I levels may
play a role in the development of the vascular complica-
tions of type 2 diabetes (5,6). IGF-I may also play a role in
the regulation of cardiovascular function (7,8) and devel-
opment of myocardial infarction in subjects without type 2
diabetes, although various studies have yielded conflicting
results regarding the direction of the association between
circulating IGF-I levels and cardiovascular disease (9–14).
Studies of the role of IGF-I in the development of disease
have been hampered by the fact that circulating IGF-I
levels do not necessarily reflect the local production of
IGF-I in specific tissues, such as the myocardium or
pancreatic b-cells. A genetic polymorphism in the IGF-I
gene promoter region has been identified, which may
influence IGF-I production (15,16). This may create an
opportunity to characterize, on a genetic basis, subjects
who are chronically exposed to low IGF-I levels through-
out the body. Until now, studies of this polymorphism in
relation to IGF-I levels and pathology have been limited to
patients with osteoporosis and related disorders (16–18).
We examined the role of a known genetic polymorphism
in the promoter region of the IGF-I gene in relation to
circulating IGF-I levels and growth measured as body
height, and we studied the relationship of this polymor-
phism with type 2 diabetes and myocardial infarction.
RESEARCH DESIGN AND METHODS
Subjects. This study is part of the Rotterdam Study, a single-center prospec-
tive follow-up study in which all residents of the Rotterdam suburb Ommoord
aged 55 years and older were invited to take part. The study was approved by
the Medical Ethics Committee of Erasmus Medical Center Rotterdam (the
Netherlands), and written informed consent was obtained from all partici-
pants. The aim of the study was to investigate determinants of chronic and
disabling cardiovascular, neurodegenerative, locomotor, and ophthalmologic
diseases. The design of the study has been described previously (19). The
baseline examination of the Rotterdam Study, on which this report is based,
was conducted between 1990 and 1993. A total of 7,983 participants (response
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rate 78%) were examined. In the present study, we only included subjects
between 55 and 75 years of age at the time of baseline examination.
We followed a five-phase approach to study the relation of a known
cytosine-adenine repeat in the promoter region of the human IGF-I gene (15)
with growth, IGF-I serum levels, and risk for type 2 diabetes and cardiovas-
cular disease. In phase 1, we selected a population-based sample of 900
participants to assess genotype and allele frequencies of the polymorphism
and their relationship with body height. The 900 subjects were randomly
drawn from all participants in the age groups of 55–65 years and 65–75 years
and were frequency matched for the age distribution of the myocardial
infarction cases (described later). The number of subjects was based on
power calculations to detect a difference in body-height of at least 1.5 cm with
a power of 80% and a significance level of 0.05. In phase 2, 50 subjects were
randomly drawn from each genotype stratum in the population-based sample.
In these subjects, the relation between the promoter polymorphism and serum
IGF-I concentration was studied. The selection of these 50 subjects per
genotype was based on power calculations to detect a difference of at least
15% in serum IGF-I concentration between genotypes with a power of 80% and
a significance level of 0.05. In phase 3, the association of the polymorphism
with type 2 diabetes was assessed in a case-control study. For practical and
financial reasons, only a proportion of the Rotterdam Study (n 5 1,110)
underwent a fasting oral glucose tolerance test. From this group, we selected
our case and control subjects. Included were patients being treated for type 2
diabetes and patients in whom type 2 diabetes had been diagnosed recently,
based on a fasting glucose level of 7.0 mmol/l or higher and/or a 2-h postload
glucose measurement of 11.1 mmol/l or higher after a fasting 75-g oral glucose
tolerance test (20). The 220 patients identified were compared with 596
normoglycemic control subjects. Normoglycemia was defined as a fasting
glucose level lower than 6.1 mmol/l and a 2-h postload glucose sample lower
than 7.8 mmol/l.
In phases 4 and 5, the association of the polymorphism with myocardial
infarction was assessed. In phase 4, 477 participants with myocardial infarc-
tion confirmed on electrocardiogram (ECG) at the baseline examination were
compared with 808 control subjects who had no evidence of myocardial
infarction on ECG. These control subjects were selected from the age-
frequency-matched population of 900 subjects of phase 1. In all participants,
a resting standard 12-lead ECG was recorded with an ACTA Gnosis IV
(EsaoteBiomedica) (21,22). To diagnose myocardial infarction, an automated
diagnostic classification system, the Modular ECG Analysis System (MEANS)
(21,22), was used. Infarctions detected without evidence of symptoms (silent
myocardial infarctions) were verified by an experienced cardiologist (21,22).
Finally, in phase 5, the relative risk for myocardial infarction in the 220
subjects with type 2 diabetes was studied in relation to the IGF-I promoter
polymorphism using the clinical criteria described above.
Measurements. At the baseline examination, information concerning health
status, drug use, and smoking behavior was obtained using a computerized
questionnaire. Height and weight were measured and BMI (kg/m2) was
calculated. Body fat distribution was assessed by the waist-to-hip ratio
(WHR). Blood pressure was measured in sitting position at the right upper arm
with a random-zero sphygmomanometer, and the average of two measure-
ments obtained at one occasion was used. Hypertension was defined as a
diastolic blood pressure of 95 mmHg or higher and/or a systolic blood
pressure of 160 or higher and/or the use of antihypertensive drugs.
Blood sampling and storage have been described elsewhere (23). Serum
was separated by centrifugation and quickly frozen in liquid nitrogen. Baseline
measurements were performed on nonfasting blood samples. Total serum
cholesterol and HDL cholesterol levels were determined using an automated
enzymatic procedure (24). Glucose levels were measured by the glucose
hexokinase method in fasting serum and postload serum samples (25). Total
IGF-I was determined by a commercially available radioimmunoassay (Med-
genix Diagnostics) with intra-assay and interassay variation of 6.1 and 9.9%,
respectively, in nonfasting serum.
Polymerase chain reaction (PCR) was performed using oligonucleotide
primers designed to amplify the polymorphic cytosine-adenine repeat 1 kb
upstream of the human IGF-I gene (15). The reaction was carried out in a final
volume of 10 ml containing 50 ng of genomic DNA obtained from peripheral
white blood cells, 0.5 nmol/l forward primer (59-ACCACTCTGGGAGAAG
GGTA-39), 0.5 nmol/l reverse primer (59-GCTAGCCAGCTGGTGTTATT-39),
0.25 mmol/l 29-dNTP, 2.2 mmol/l MgCl2, 0.01% W1 (Gibco BRL), and 0.4 U Taq
DNA polymerase (Gibco BRL). PCR was performed in 384 well plates (94°C 10
min; 35 PCR cycles of 30 s at 94°C, 30 s on 55°C, and 30 s on 72°C; 72°C 10 min;
4°C hold). Forward primers were labeled with FAM, HEX, or NED to
determine the size of PCR products by autosequencer (ABI 377, 6.25%
longranger gel, filter set D, peak height between 100 and 2,000, each lane
containing three samples). The size of the PCR products was determined in
comparison with internal ROX 500-size standard (Perkin Elmer).
Statistical analysis. Hardy-Weinberg equilibrium of the IGF-I promoter
polymorphism genotypes was tested with the GENEPOP-package (26). Body
height and serum IGF-I concentration were compared between genotypes
using analyses of variance. Body height was adjusted for the possible
confounders age and sex. Participants who were taking medications for type
2 diabetes or hormone conditions were excluded from the analyses of serum
IGF-I, because these types of medication are known to influence IGF-I
concentrations (27–29). Furthermore, serum IGF-I was adjusted for the
possible confounders age, sex, and BMI. Serum IGF-I values were logarithmi-
cally transformed for the analyses. The nontransformed data and standard
errors are presented for both body height and IGF-I.
A multiple logistic regression model was used to study the association of
the IGF-I promoter polymorphism genotypes with type 2 diabetes and
myocardial infarction. Each patient group was compared with the specific
control group selected. Relative risks were estimated as odds ratios and
presented with a 95% CI. Both crude relative risks and relative risks after
adjustment for the possible confounders age, sex, body height, BMI, WHR,
total cholesterol level, HDL cholesterol level, and hypertension are presented
in Table 1. All analyses were performed using the SPSS for Windows (version
7.5.2) software package.
RESULTS
The characteristics of the participants in the studies are
presented in Table 1. In both the myocardial infarction
study and type 2 diabetes study, case subjects were
slightly older and included more men. BMI was signifi-
cantly increased in patients with type 2 diabetes, whereas
the WHR was significantly increased both in patients with
type 2 diabetes and patients with myocardial infarction.
Low HDL cholesterol levels and hypertension were fre-
quently seen in both case groups. In the population-based
sample of 900 subjects, 10 different alleles were identified
in the promoter polymorphism of the IGF-I gene (Table 2).
Genotype and allele distributions were in Hardy-Weinberg
TABLE 1
Baseline characteristics of the study populations
Population sample
Diabetes study Myocardial infarction study
Case subjects Control subjects Case subjects Control subjects
n 900 220 596 477 808
Age (years) 65.9 (5.6) 68.2 (5.6)† 66.2 (5.4) 66.5 (5.2)* 65.7 (5.6)
Men 39.9% 56.4%* 47.3% 69.2%† 38.6%
Current smokers 25.3% 20.1% 24.1% 26.5% 25.2%
BMI (kg/m2) 26.6 (3.8) 27.6 (3.5)* 25.9 (3.2) 26.6 (3.8) 26.6 (3.6)
WHR 0.90 (0.09) 0.94 (0.09)† 0.89 (0.09) 0.94 (0.08)† 0.90 (0.09)
Total cholesterol level (mmol/l) 6.8 (1.2) 6.4 (1.2) 6.6 (1.1) 6.6 (1.2) 6.8 (1.2)
HDL cholesterol level (mmol/l) 1.4 (0.3) 1.2 (0.3)† 1.4 (0.3) 1.2 (0.3)† 1.4 (0.3)
Hypertension 38.6% 55.7%† 31.7% 59.1%† 36.6%
Data are means (SD) or percentages. *P 5 0.05; †P 5 0.005.
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equilibrium (P 5 0.76). When considering genotypes, 88.4%
of the subjects from the population-based sample were
homozygous or heterozygous for a 192-bp allele, suggest-
ing that this is the wild-type allele from which all other
alleles originated. The frequency of the other nine alleles
was low; therefore, these alleles were pooled in the
analyses. This resulted in three possible genotypes: sub-
jects who were homozygous for the 192-bp allele (46.7%),
subjects who were heterozygous for the 192-bp allele
(41.7%), and noncarriers of the 192-bp allele (11.6%).
In the population-based sample of 900 subjects, body
height increased with the number of 192-bp alleles pres-
ent (P for trend 5 0.01, Fig. 1A). Mean body height was
significantly lower in noncarriers of the 192-bp allele
(165.4 cm) compared with subjects who were homozygous
for the 192-bp allele (168.1 cm [95% CI for difference –4.6
to –0.8 cm, P 5 0.004]). Also, the mean serum IGF-I
increased with the number of 192-bp alleles carried (P for
trend 5 0.003, Fig. 1B). In noncarriers of the 192-bp allele,
the mean serum total IGF-I concentration was 18% lower
(16.7 mmol/l) compared with subjects who were homozy-
gous for the 192-bp allele (20.5 mmol/l [95% CI for differ-
ence –6.0 to –1.3 mmol/l, P 5 0.003]). The findings related
to body height and IGF-I levels could not be attributed to
a specific allele of the IGF-I promoter polymorphism.
As demonstrated in Table 3, the IGF-I genotype is not
associated with previously identified correlates of myocar-
dial infarction or type 2 diabetes. As shown in Table 4,
fewer subjects with type 2 diabetes or myocardial infarc-
tion were homozygous for the 192-bp allele compared with
the control groups. Compared with subjects who were
homozygous for the 192-bp allele, noncarriers of the
192-bp allele had a relative risk of 1.7 for developing type
2 diabetes (95% CI 1.1–2.7) as well as for myocardial
infarction (95% CI 1.1–2.5). For subjects who were het-
erozygous for the 192-bp allele, the relative risk was 1.4 for
developing type 2 diabetes (95% CI 1.0–1.9) and 1.2 for
developing myocardial infarction (95% CI 0.9–1.5). Al-
though the IGF-I polymorphism was strongly associated
with body height, no statistically significant association
between body height and type 2 diabetes or myocardial
infarction was found. However, comparing body height
with control subjects, on average, patients with type 2
diabetes were 0.6 cm shorter (P 5 0.23) and patients with
myocardial infarction were 0.4 cm shorter (P 5 0.29).
Correction for these small differences in body height in our
analysis did not change the risk estimates for type 2
diabetes or myocardial infarction associated with the
IGF-I genotype. Within the group of patients with type 2
diabetes, 34 subjects with myocardial infarction were
identified. The prevalence of myocardial infarction was
25% in subjects without the 192-bp allele (Fig. 2). In
noncarriers of the 192-bp allele, the relative risk for
myocardial infarction was 3.4 (95% CI 1.1–11.3), whereas
for subjects who were heterozygous for the 192-bp allele,
TABLE 2
Allele distribution of the IGF-I promoter polymorphism
Allele







200 1 (0.1) — 1 (0.1)
198 9 (1.3) 16 (1.5) 25 (1.4)
196 44 (6.1) 80 (7.4) 124 (6.9)
194 118 (16.4) 202 (18.7) 320 (17.8)
192 505 (70.1) 712 (65.9) 1,217 (67.6)
190 26 (3.6) 44 (4.1) 70 (3.9)
188 15 (2.1) 21 (1.9) 36 (2.0)
186 2 (0.3) 3 (0.3) 5 (0.3)
184 — 2 (0.2) 2 (0.1)
182 1 (0.1) — 1 (0.1)
Data are n (%). *Allele distribution based on a population-based
sample of 900 participants (1,800 alleles: 2 alleles per subject).
FIG. 1. Body height and serum IGF-I level in relation to the IGF-I
promoter polymorphism. A: Body height as mean with standard error.
B: Mean serum IGF-I concentration with standard error (mmol/l).
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the relative risk for myocardial infarction was 2.9 (95% CI
1.1–7.7).
DISCUSSION
In this population-based study, we found that the absence
of the wild-type (192-bp) allele of a genetic polymorphism
in the regulatory region of the IGF-I gene is significantly
associated with low body height and low serum levels of
IGF-I. The main finding of the study is that the absence of
this allele is also significantly associated with an increased
risk for type 2 diabetes and myocardial infarction. Partic-
ularly in subjects with type 2 diabetes, the relative risk for
myocardial infarction is strongly increased in subjects
who are noncarriers of the 192-bp allele.
The polymorphism under study is a cytosine-adenosine
repeat 1 kb upstream from the transcription site of the
IGF-I gene (30). Given the population-based approach of
our study, we cannot distinguish whether this polymor-
phism itself is involved in regulation of IGF-I expression or
merely flags another polymorphism in the promoter region
functionally involved in IGF-I expression. However, the
association with low body height and low IGF-I serum
level suggests that the absence of the 192-bp allele char-
acterizes subjects who are chronically exposed to low
IGF-I levels throughout the body. Using this polymor-
phism, the difficulty in measuring local IGF-I production in
relevant tissues, such as the myocardium or the pancreatic
b-cell, can be circumvented. Furthermore, this genetic
approach overcomes the problem that cross-sectional
studies cannot distinguish whether changes in IGF-I levels
are a cause or rather a consequence of disease.
In our population-based sample from the Rotterdam
Study, the 192-bp allele was present in 88% of subjects.
This finding is in agreement with other reports in Cauca-
sian populations (16,17). In contrast with a previous report
by Rosen et al. (16), subjects who were homozygous for
the 192-bp allele had significantly higher serum levels of
IGF-I compared with subjects who were noncarriers of
this allele. However, the study by Rosen et al. was based
on a relatively small, highly selected study population that
included patients with chronic chest pain, patients with
idiopathic osteoporosis, participants of a calcium inter-
vention trial, and participants of a study on body mass
(16). The inclusion of patients with putative IGF-I–related
pathology might explain the discrepancy with the findings
in our population-based study. Our observation of high
IGF-I concentrations in subjects who were homozygous
for the 192-bp allele are supported by the fact that these
subjects were also significantly taller by nearly 3 cm
compared with subjects who were noncarriers of the
192-bp allele.
This is the first study of the role of the IGF-I promoter
polymorphism in the pathogenesis of type 2 diabetes and
cardiovascular disease. The increased relative risk for type
2 diabetes and myocardial infarction in noncarriers of the
192-bp allele suggests that a lifetime exposure to moderate
alterations in IGF-I expression may also be biologically
relevant in terms of disease risk. These observations are in
accordance with earlier reports of low-normal circulating
IGF-I levels in patients with cardiovascular disease (31)
and type 2 diabetes (3). Considering the association with
both myocardial infarction and type 2 diabetes, this IGF-I
promoter polymorphism may explain, to some extent, the
clustering of these diseases. The polymorphism is a par-
ticularly strong predictor of myocardial infarction in sub-
jects with type 2 diabetes. If these findings can be
replicated by others, this may present an opportunity to
identify patients with type 2 diabetes who are at high risk
for myocardial infarction and who may benefit from
specific therapy influencing the IGF-I metabolism. Further
TABLE 3
Relation between IGF-I promoter genotype and previously identified correlates of type 2 diabetes or myocardial infarction
Homozygous 192-bp allele Heterozygous 192-bp allele Noncarrier 192-bp allele P
Age (years) 66.4 (5.4) 65.4 (5.6) 66.1 (6.0) 0.11
Men 179 (42.4%) 147 (39.2%) 34 (32.7%) 0.18
Current smokers 98 (23.4%) 108 (29.0%) 21 (20.6%) 0.30
BMI (kg/m2) 26.6 (3.9) 26.8 (3.8) 26.5 (3.0) 0.71
WHR 0.90 (0.09) 0.91 (0.09) 0.90 (0.1) 0.52
Total cholesterol level (mmol/l) 6.8 (1.3) 6.8 (1.2) 6.7 (0.9) 0.93
HDL cholesterol level (mmol/l) 1.3 (0.4) 1.4 (0.4) 1.4 (0.3) 0.27
Hypertension 170 (40.5%) 140 (37.3%) 37 (35.6%) 0.53
Data are means (SD) or n (%). Measurements based on population sample of 900 subjects.
TABLE 4
Relative risk of type 2 diabetes and myocardial infarction based on the presence of the 192-bp allele
Homozygous 192-bp allele Heterozygous 192-bp allele Noncarrier 192-bp allele
Type 2 diabetes 83 (37.7%) 102 (46.4%) 35 (15.9%)
Control subjects 277 (46.5%) 248 (41.6%) 71 (11.9%)
Crude relative risk Reference 1.4 (1.0–1.9) 1.6 (1.0–2.6)
Adjusted relative risk* Reference 1.4 (1.0–1.9) 1.7 (1.1–2.7)
Myocardial infarction 205 (43.0%) 204 (42.8%) 68 (14.3%)
Control subjects 383 (47.4%) 340 (42.1%) 85 (10.5%)
Crude relative risk Reference 1.1 (0.9–1.4) 1.5 (1.0–2.1)
Adjusted relative risk* Reference 1.2 (0.9–1.5) 1.7 (1.1–2.5)
Data are number of subjects for each category (% of case subjects or control subjects). Risks are given with a 95% CI. *Adjustment for the
possible confounders age, sex, WHR, BMI, total cholesterol level, HDL cholesterol level, and hypertension.
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studies are needed for a better understanding of the
specific pathogenic pathways involved.
Our population-based study suggests that a genetic
polymorphism in the promoter region of the IGF-I gene is
associated with IGF-I expression. The absence of a 192-bp
allele of this polymorphism, as observed in almost 12% of
the general population, is associated with lower body
height, low IGF-1 levels, and an increased risk for type 2
diabetes and myocardial infarction. The increased risk for
these disorders is most likely a result of a genetically
determined, lifelong exposure to relatively low IGF-I con-
centrations in subjects who are noncarriers of the 192-bp
allele.
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